Glucose intolerance during hormonal therapy for prostate cancer

Abstract

The aim of this study was to examine the influence of hormonal therapy (HT) on glucose metabolism in prostate cancer (PCa) patients. Fifty-two PCa patients receiving HT with gonadotropin-releasing hormone (GnRH) analogues and/or antiandrogen drugs were enrolled in this study. Both blood and urine samples were taken a few hours after breakfast before and after HT, and glucose levels in the blood and urine were measured. Elevations of blood glucose levels of 30-50, 50-100 and over 100 mg/dl after HT as compared with the levels before HT were observed in two, eight and five patients, respectively. Urine examination revealed deterioration of glucosuria in seven patients. The mean blood glucose level after HT was significantly higher than that measured before HT. The elevation of blood glucose level significantly correlated with concurrence of diabetes mellitus (DM) and higher body mass index (BMI) before HT. Deterioration of glucosuria significantly correlated with the concurrence of DM. HT for PCa patients, especially with concurrent DM or obesity, induces elevation of the blood glucose level and deterioration of glucosuria. Therefore, glucose intolerance should be considered during HT for PCa.

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

“…During the first year of treatment with LHRHa, increases of total cholesterol concentrations by 5–10% and of HDL cholesterol by 6–12% have been reported in several small studies 31–34 . Observed increases in fasting glucose concentrations by 1–2% have also been seen in short-term (12-week) studies, 35,36 and larger changes have been seen in one longer-term study 34 . These results are again consistent with our findings (increases of 2% and 6% in fasting glucose concentrations at 6 and 12 months, respectively).…”

High Glucose Promotes Pancreatic Cancer Cell Proliferation via the Induction of EGF Expression and Transactivation of EGFR

“…High glucose has different actions in dissimilar target organs. For example, high glucose induces cell growth or hyperplasia in pancreatic cancer [5], breast cancer [19] and mesangial cells [11], [32], but reduces cell growth in cornea [31] and prostate cancer [33]. In addition, the mechanism of high glucose on phosphorylation of EGFR is obscure and complicated.…”

Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure

“…10,24 Changes in glucose metabolism in ADT patients also vary based on diabetic status with greater increases in those with diabetes (48%) compared to nondiabetic patients (7%) following a median ADT treatment duration of 44 weeks. 30 Further, ADT-induced hypogonadal men have shown higher fasting levels of total cholesterol, low-density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (HDL) cholesterol than non-ADT prostate cancer men and age-matched controls. 12 However, contrasting the classical pattern of metabolic syndrome, concomitant increases in both LDL and HDL cholesterol have also been reported.…”